Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition

• Glucose-Lowering and Metabolic Effects of SGLT2 InhibitorsRenoprotective Effects of SGLT2 InhibitorsSGLT2 Inhibitors in Type 2 Diabetes MellitusSGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal ProtectionSGLT2 Inhibitors and Heart Failure with Preserved Ejection FractionSGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical BenefitsSodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease EventsSGLT2 Inhibitors and Peripheral Vascular Events: A Review of the LiteratureSodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver DiseaseSGLT2 Inhibitors and Safety in Older PatientsSodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition

• Glucose-Lowering and Metabolic Effects of SGLT2 InhibitorsRenoprotective Effects of SGLT2 InhibitorsSGLT2 Inhibitors in Type 2 Diabetes MellitusSGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal ProtectionSGLT2 Inhibitors and Heart Failure with Preserved Ejection FractionSGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical BenefitsSodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease EventsSGLT2 Inhibitors and Peripheral Vascular Events: A Review of the LiteratureSodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver DiseaseSGLT2 Inhibitors and Safety in Older PatientsSodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk

Deepak L. Bhatt, MD, MPH, is Executive Director of Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center and Professor of Medicine at Harvard Medical School. A leading authority internationally on interventional cardiology in addition

• Glucose-Lowering and Metabolic Effects of SGLT2 InhibitorsRenoprotective Effects of SGLT2 InhibitorsSGLT2 Inhibitors in Type 2 Diabetes MellitusSGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal ProtectionSGLT2 Inhibitors and Heart Failure with Preserved Ejection FractionSGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical BenefitsSodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease EventsSGLT2 Inhibitors and Peripheral Vascular Events: A Review of the LiteratureSodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver DiseaseSGLT2 Inhibitors and Safety in Older PatientsSodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk